Drug Discovery World

OCTOBER 25, 2022

Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. . Listen here.

Recombinant DNA Technology 52

Recombinant DNA Technology DNA Drugs Protein 52

Drug Discovery World

OCTOBER 25, 2022

Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. .

Recombinant DNA Technology 52

Recombinant DNA Technology DNA Drugs Protein 52

Pharmaceutical Technology

FEBRUARY 24, 2023

Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. It is based on DuoBody technology platform. It is formulated as solution and concentrate for solution for intravenous infusion.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Roots Analysis

JANUARY 21, 2024

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

Drug Discovery World

DECEMBER 29, 2022

Recombinant DNA technology and its impact on modern drug discovery . Exploring the microbiome: how it is shaping preclinical research . Catch up on the Sitting Down With podcast episodes released in 2022: . How to accelerate mouse model generation without reducing quality . Narrated Podcasts.

Recombinant DNA Technology 52

Recombinant DNA Technology Genome Genomics DNA 52

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. These IPs pose the lowest risk amongst all recombinant IPs.

Genetic Engineering 52

Genetic Engineering Clinical Trials Clinical Trials Engineer 52

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 83

Gene Immune Response Manufacturing Gene Therapy 83